← Leaderboards
George R Uhl
National Institute On Drug Abuse
$7,833,243
Attributed
$8,575,037
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,575,037 · 2
By mechanism
U01$5,034,896 · 1
UG3$3,540,141 · 1
Top collaborators
- Karin N Westlund-High1 shared
Most similar at National Institute On Drug Abuse
Same institution · by research overlap
Others in their field
Other Emerging Leaders on “Cocaine”
- Jeffrey Reich · Sparian Biosciences, Inc.$6,903,733
- Mary F. Morrison · Temple Univ Of The Commonwealth$5,117,685
- Yao-Ying Ma · State University Of Ny,Binghamton$4,919,719
- Lindsey Ingerman James · Univ Of North Carolina Chapel Hill$4,429,846
- Jian Feng · Florida State University$4,018,265
- Gina L.c. Yosten · Saint Louis University$3,898,891
Research focus
CocaineGenesReportingAddictionBrainBasePharmaceutical PreparationsIndividual DifferencesVariantSmoking CessationHaplotypesGeneticResponseSuccessRewardsPreferenceDopamineAmphetaminesCell Adhesion MoleculesDopamine TransporterReceptorDrug AbusePhenotypeDose
Grant awards (95)
PTPRD phosphatase inhibitors for stimulant use disorders$155,345
UG3 · FY2024 · DA · contact PI
PTPRD Phosphatase inhibitors for stimulant use disorders$153,168
UG3 · FY2024 · DA · contact PI
PTPRD phosphatase inhibitors for stimulant use disorders$1,391,482
UG3 · FY2023 · DA · contact PI
PTPRD phosphatase inhibitors for stimulant use disorders$386,250
UG3 · FY2023 · DA · contact PI
PTPRD phosphatase inhibitors for stimulant use disorders$1,453,896
UG3 · FY2022 · DA · contact PI
PTPRD ligands for stimulant and opiate use disorders$1,483,588
U01 · FY2021 · DA
Alzheimer's disease pYGSK3 pathophysiology and PTPRD positive allosteric modulators$349,443
U01 · FY2021 · DA · contact PI
PTPRD ligands for stimulant and opiate use disorders$1,531,273
U01 · FY2020 · DA · contact PI
PTPRD ligands for stimulant and opiate use disorders$315,055
U01 · FY2020 · DA · contact PI
PTPRD ligands for stimulant and opiate use disorders$1,355,537
U01 · FY2019 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$578,106
ZIA · FY2016 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$659,399
ZIA · FY2015 · DA · contact PI
Understanding addiction vulnerability genes$202,892
ZIA · FY2015 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$101,446
ZIA · FY2015 · DA · contact PI
Molecular Genetic Bases for Quit Success$50,723
ZIA · FY2015 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$1,174,785
ZIA · FY2014 · DA · contact PI
Understanding addiction vulnerability genes$361,472
ZIA · FY2014 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$180,736
ZIA · FY2014 · DA · contact PI
Molecular Genetic Bases for Quit Success$90,368
ZIA · FY2014 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$1,320,381
ZIA · FY2013 · DA · contact PI
Understanding addiction vulnerability genes$176,051
ZIA · FY2013 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$176,051
ZIA · FY2013 · DA · contact PI
Molecular Genetic Bases for Quit Success$88,025
ZIA · FY2013 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$1,022,479
ZIA · FY2012 · DA · contact PI
Understanding addiction vulnerability genes$557,716
ZIA · FY2012 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$185,905
ZIA · FY2012 · DA · contact PI
Molecular Genetic Bases for Quit Success$92,953
ZIA · FY2012 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$1,030,087
ZIA · FY2011 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$515,043
ZIA · FY2011 · DA · contact PI
Molecular Genetic Bases for Quit Success$412,035
ZIA · FY2011 · DA · contact PI
Understanding addiction vulnerability genes$103,009
ZIA · FY2011 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$1,570,900
ZIA · FY2010 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$785,450
ZIA · FY2010 · DA · contact PI
Molecular Genetic Bases for Quit Success$628,360
ZIA · FY2010 · DA · contact PI
Understanding addiction vulnerability genes$157,090
ZIA · FY2010 · DA · contact PI
Molecular Genetic Bases for Quit Success$1,509,084
ZIA · FY2009 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$1,433,629
ZIA · FY2009 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$528,179
ZIA · FY2009 · DA · contact PI
Understanding addiction vulnerability genes$301,817
ZIA · FY2009 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$1,948,128
Z01 · FY2008 · DA · contact PI
Molecular Genetic Bases for Quit Success$935,102
Z01 · FY2008 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$662,364
Z01 · FY2008 · DA · contact PI
Understanding addiction vulnerability genes$350,663
Z01 · FY2008 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Humans$2,646,398
Z01 · FY2007 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: Mice$793,919
Z01 · FY2007 · DA · contact PI
Understanding addiction vulnerability genes$423,424
Z01 · FY2007 · DA · contact PI
Synaptic Vesicular Monamine Transporter$264,640
Z01 · FY2007 · DA · contact PI
Mu Opiate Receptors$105,856
Z01 · FY2007 · DA · contact PI
Dopamine Transporter--Structure/function Studies Of Transporter And Promoters$52,928
Z01 · FY2007 · DA · contact PI
Mu Opiate Receptors$0
Z01 · FY2006 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And$0
Z01 · FY2006 · DA · contact PI
Genetic Approaches To Characterizing Drug Responses And$0
Z01 · FY2006 · DA · contact PI
Synaptic Vesicular Monamine Transporter$0
Z01 · FY2006 · DA · contact PI
Dopaminergic Genes$0
Z01 · FY2006 · DA · contact PI
Dopamine Transporter--Structure/function Studies Of Tran$0
Z01 · FY2006 · DA · contact PI
Genes Regulated By Abused Drugs$0
Z01 · FY2006 · DA · contact PI
Understanding addiction vulnerability genes$0
Z01 · FY2006 · DA · contact PI
Genes Regulated By Abused Drugs$0
Z01 · FY2005 · DA
Mu Opiate Receptors$0
Z01 · FY2005 · DA
Genetic Approaches To Characterizing Drug Responses$0
Z01 · FY2005 · DA
Genetic Approaches To Characterizing Drug Responses$0
Z01 · FY2005 · DA
Synaptic Vesicular Monamine Transporter$0
Z01 · FY2005 · DA
Dopaminergic Genes$0
Z01 · FY2005 · DA
Dopamine Transporter Regulation$0
Z01 · FY2005 · DA
Dopamine Transporter--Structure/function Studies$0
Z01 · FY2005 · DA
Dopamine Transporter--structure/function Studies Of Tran$0
Z01 · FY2004 · DA
Genetic Approaches To Characterizing Drug Responses And$0
Z01 · FY2004 · DA
Genetic Approaches To Characterizing Drug Responses$0
Z01 · FY2004 · DA
Synaptic Vesicular Monoamine Transporter$0
Z01 · FY2004 · DA
Dopamine Transporter Regulation$0
Z01 · FY2004 · DA
Genes Regulated By Abused Drugs$0
Z01 · FY2004 · DA
Dopamine Transporter--structure/function Studies Of Tran$0
Z01 · FY2003 · DA
Mu Opiate Receptors$0
Z01 · FY2003 · DA
Genetic Approaches To Characterizing Drug Responses And$0
Z01 · FY2003 · DA
Genetic Approaches To Characterizing Drug Responses And$0
Z01 · FY2003 · DA
Synaptic Vesicular Monamine Transporter$0
Z01 · FY2003 · DA
Dopaminergic Genes$0
Z01 · FY2003 · DA
Dopamine Transporter Regulation$0
Z01 · FY2003 · DA
Genes Regulated By Abused Drugs$0
Z01 · FY2003 · DA
Genes Regulated By Abused Drugs$0
Z01 · FY2002 · DA
Mu Opiate Receptors$0
Z01 · FY2002 · DA
Genetic Approaches To Characterizing Drug Responses And$0
Z01 · FY2002 · DA
Genetic Approaches To Characterizing Drug Responses And$0
Z01 · FY2002 · DA
Synaptic Vesicular Monamine Transporter$0
Z01 · FY2002 · DA
Dopaminergic Genes$0
Z01 · FY2002 · DA
Dopamine Transporter Regulation$0
Z01 · FY2002 · DA
Dopamine Transporter--structure/function Studies Of Tran$0
Z01 · FY2002 · DA
GENES REGULATED BY ABUSED DRUGS$0
Z01 · FY2000 · DA
MU OPIATE RECEPTORS$0
Z01 · FY2000 · DA
GENETIC APPROACHES TO CHARACTERIZING DRUG RESPONSES AND VULNERABILITIES: HUMANS$0
Z01 · FY2000 · DA
GENETIC APPROACHES TO CHARACTERIZING DRUG RESPONSES AND VULNERABILITIES: MICE$0
Z01 · FY2000 · DA
SYNAPTIC VESICULAR MONAMINE TRANSPORTER$0
Z01 · FY2000 · DA
DOPAMINE TRANSPORTER-HUMAN &MOUSE GENES, DOPAMINERGIC DISORDERS &KNOCKOUT MICE$0
Z01 · FY2000 · DA
DOPAMINE TRANSPORTER REGULATION$0
Z01 · FY2000 · DA
DOPAMINE TRANSPORTER--STRUCTURE/FUNCTION STUDIES OF TRANSPORTER AND LIGANDS$0
Z01 · FY2000 · DA